nodes	percent_of_prediction	percent_of_DWPC	metapath
Linagliptin—CYP3A4—bone cancer	0.94	1	CbGaD
Linagliptin—ABCB1—Cisplatin—bone cancer	0.00842	0.368	CbGbCtD
Linagliptin—Alogliptin—CYP3A4—bone cancer	0.00791	1	CrCbGaD
Linagliptin—ABCB1—Doxorubicin—bone cancer	0.00564	0.246	CbGbCtD
Linagliptin—ABCB1—Methotrexate—bone cancer	0.00547	0.239	CbGbCtD
Linagliptin—CYP3A4—Doxorubicin—bone cancer	0.00338	0.148	CbGbCtD
Linagliptin—Bronchial hyperreactivity—Methotrexate—bone cancer	0.00187	0.0638	CcSEcCtD
Linagliptin—Diabetic—Methotrexate—bone cancer	0.00147	0.0499	CcSEcCtD
Linagliptin—Infection—Carboplatin—bone cancer	0.00108	0.0367	CcSEcCtD
Linagliptin—Skin exfoliation—Cisplatin—bone cancer	0.000851	0.029	CcSEcCtD
Linagliptin—Hyperlipidaemia—Epirubicin—bone cancer	0.000635	0.0216	CcSEcCtD
Linagliptin—Hyperlipidaemia—Doxorubicin—bone cancer	0.000588	0.02	CcSEcCtD
Linagliptin—Nasopharyngitis—Cisplatin—bone cancer	0.000579	0.0197	CcSEcCtD
Linagliptin—Pancreatitis—Cisplatin—bone cancer	0.000548	0.0187	CcSEcCtD
Linagliptin—Skin exfoliation—Methotrexate—bone cancer	0.000467	0.0159	CcSEcCtD
Linagliptin—Skin exfoliation—Epirubicin—bone cancer	0.000437	0.0149	CcSEcCtD
Linagliptin—Diabetes mellitus—Methotrexate—bone cancer	0.000408	0.0139	CcSEcCtD
Linagliptin—Skin exfoliation—Doxorubicin—bone cancer	0.000405	0.0138	CcSEcCtD
Linagliptin—Immune system disorder—Cisplatin—bone cancer	0.000404	0.0138	CcSEcCtD
Linagliptin—Mediastinal disorder—Cisplatin—bone cancer	0.000404	0.0137	CcSEcCtD
Linagliptin—Malnutrition—Cisplatin—bone cancer	0.00039	0.0133	CcSEcCtD
Linagliptin—Diabetes mellitus—Epirubicin—bone cancer	0.000382	0.013	CcSEcCtD
Linagliptin—Diabetes mellitus—Doxorubicin—bone cancer	0.000354	0.012	CcSEcCtD
Linagliptin—Hypoglycaemia—Epirubicin—bone cancer	0.000341	0.0116	CcSEcCtD
Linagliptin—Pain in extremity—Epirubicin—bone cancer	0.000332	0.0113	CcSEcCtD
Linagliptin—Myalgia—Cisplatin—bone cancer	0.000332	0.0113	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.00033	0.0112	CcSEcCtD
Linagliptin—Anaphylactic shock—Cisplatin—bone cancer	0.000318	0.0108	CcSEcCtD
Linagliptin—Infection—Cisplatin—bone cancer	0.000316	0.0108	CcSEcCtD
Linagliptin—Hypoglycaemia—Doxorubicin—bone cancer	0.000315	0.0107	CcSEcCtD
Linagliptin—Skin disorder—Cisplatin—bone cancer	0.000309	0.0105	CcSEcCtD
Linagliptin—Pain in extremity—Doxorubicin—bone cancer	0.000308	0.0105	CcSEcCtD
Linagliptin—Pancreatitis—Methotrexate—bone cancer	0.000301	0.0102	CcSEcCtD
Linagliptin—Nasopharyngitis—Epirubicin—bone cancer	0.000297	0.0101	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Cisplatin—bone cancer	0.00029	0.00986	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Methotrexate—bone cancer	0.000285	0.00971	CcSEcCtD
Linagliptin—Pancreatitis—Epirubicin—bone cancer	0.000282	0.00959	CcSEcCtD
Linagliptin—Nasopharyngitis—Doxorubicin—bone cancer	0.000275	0.00936	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Cisplatin—bone cancer	0.000275	0.00935	CcSEcCtD
Linagliptin—Infestation NOS—Methotrexate—bone cancer	0.000274	0.00932	CcSEcCtD
Linagliptin—Infestation—Methotrexate—bone cancer	0.000274	0.00932	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Epirubicin—bone cancer	0.000267	0.00909	CcSEcCtD
Linagliptin—Weight increased—Epirubicin—bone cancer	0.000261	0.0089	CcSEcCtD
Linagliptin—Pancreatitis—Doxorubicin—bone cancer	0.000261	0.00887	CcSEcCtD
Linagliptin—Infestation NOS—Epirubicin—bone cancer	0.000256	0.00872	CcSEcCtD
Linagliptin—Infestation—Epirubicin—bone cancer	0.000256	0.00872	CcSEcCtD
Linagliptin—Urinary tract infection—Epirubicin—bone cancer	0.000249	0.00847	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000247	0.00841	CcSEcCtD
Linagliptin—Weight increased—Doxorubicin—bone cancer	0.000242	0.00823	CcSEcCtD
Linagliptin—Infestation—Doxorubicin—bone cancer	0.000237	0.00807	CcSEcCtD
Linagliptin—Infestation NOS—Doxorubicin—bone cancer	0.000237	0.00807	CcSEcCtD
Linagliptin—Hypersensitivity—Cisplatin—bone cancer	0.000234	0.00798	CcSEcCtD
Linagliptin—Urinary tract infection—Doxorubicin—bone cancer	0.00023	0.00784	CcSEcCtD
Linagliptin—Immune system disorder—Methotrexate—bone cancer	0.000222	0.00755	CcSEcCtD
Linagliptin—Mediastinal disorder—Methotrexate—bone cancer	0.000221	0.00754	CcSEcCtD
Linagliptin—Diarrhoea—Cisplatin—bone cancer	0.000218	0.00741	CcSEcCtD
Linagliptin—Malnutrition—Methotrexate—bone cancer	0.000214	0.00728	CcSEcCtD
Linagliptin—Immune system disorder—Epirubicin—bone cancer	0.000208	0.00707	CcSEcCtD
Linagliptin—Mediastinal disorder—Epirubicin—bone cancer	0.000207	0.00705	CcSEcCtD
Linagliptin—Back pain—Methotrexate—bone cancer	0.000207	0.00704	CcSEcCtD
Linagliptin—Rash—Cisplatin—bone cancer	0.000201	0.00683	CcSEcCtD
Linagliptin—Dermatitis—Cisplatin—bone cancer	0.0002	0.00682	CcSEcCtD
Linagliptin—Malnutrition—Epirubicin—bone cancer	0.0002	0.00681	CcSEcCtD
Linagliptin—Back pain—Epirubicin—bone cancer	0.000194	0.00659	CcSEcCtD
Linagliptin—Immune system disorder—Doxorubicin—bone cancer	0.000192	0.00654	CcSEcCtD
Linagliptin—Mediastinal disorder—Doxorubicin—bone cancer	0.000192	0.00653	CcSEcCtD
Linagliptin—Cough—Methotrexate—bone cancer	0.000187	0.00635	CcSEcCtD
Linagliptin—Malnutrition—Doxorubicin—bone cancer	0.000185	0.0063	CcSEcCtD
Linagliptin—Arthralgia—Methotrexate—bone cancer	0.000182	0.0062	CcSEcCtD
Linagliptin—Myalgia—Methotrexate—bone cancer	0.000182	0.0062	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000181	0.00616	CcSEcCtD
Linagliptin—Back pain—Doxorubicin—bone cancer	0.000179	0.0061	CcSEcCtD
Linagliptin—Cough—Epirubicin—bone cancer	0.000175	0.00594	CcSEcCtD
Linagliptin—Anaphylactic shock—Methotrexate—bone cancer	0.000175	0.00594	CcSEcCtD
Linagliptin—Infection—Methotrexate—bone cancer	0.000173	0.0059	CcSEcCtD
Linagliptin—Arthralgia—Epirubicin—bone cancer	0.00017	0.0058	CcSEcCtD
Linagliptin—Myalgia—Epirubicin—bone cancer	0.00017	0.0058	CcSEcCtD
Linagliptin—Skin disorder—Methotrexate—bone cancer	0.00017	0.00577	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000169	0.00576	CcSEcCtD
Linagliptin—Anaphylactic shock—Epirubicin—bone cancer	0.000163	0.00556	CcSEcCtD
Linagliptin—Infection—Epirubicin—bone cancer	0.000162	0.00552	CcSEcCtD
Linagliptin—Cough—Doxorubicin—bone cancer	0.000162	0.0055	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000159	0.00541	CcSEcCtD
Linagliptin—Skin disorder—Epirubicin—bone cancer	0.000159	0.0054	CcSEcCtD
Linagliptin—Arthralgia—Doxorubicin—bone cancer	0.000158	0.00537	CcSEcCtD
Linagliptin—Myalgia—Doxorubicin—bone cancer	0.000158	0.00537	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000157	0.00533	CcSEcCtD
Linagliptin—Anaphylactic shock—Doxorubicin—bone cancer	0.000151	0.00514	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Methotrexate—bone cancer	0.000151	0.00513	CcSEcCtD
Linagliptin—Infection—Doxorubicin—bone cancer	0.00015	0.00511	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000149	0.00507	CcSEcCtD
Linagliptin—Skin disorder—Doxorubicin—bone cancer	0.000147	0.005	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Epirubicin—bone cancer	0.000141	0.0048	CcSEcCtD
Linagliptin—Constipation—Epirubicin—bone cancer	0.00014	0.00475	CcSEcCtD
Linagliptin—Urticaria—Methotrexate—bone cancer	0.000139	0.00472	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000138	0.00469	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000131	0.00444	CcSEcCtD
Linagliptin—Urticaria—Epirubicin—bone cancer	0.00013	0.00442	CcSEcCtD
Linagliptin—Constipation—Doxorubicin—bone cancer	0.000129	0.0044	CcSEcCtD
Linagliptin—Hypersensitivity—Methotrexate—bone cancer	0.000129	0.00438	CcSEcCtD
Linagliptin—Hypersensitivity—Epirubicin—bone cancer	0.00012	0.0041	CcSEcCtD
Linagliptin—Urticaria—Doxorubicin—bone cancer	0.00012	0.00409	CcSEcCtD
Linagliptin—Diarrhoea—Methotrexate—bone cancer	0.000119	0.00407	CcSEcCtD
Linagliptin—Diarrhoea—Epirubicin—bone cancer	0.000112	0.0038	CcSEcCtD
Linagliptin—Hypersensitivity—Doxorubicin—bone cancer	0.000111	0.00379	CcSEcCtD
Linagliptin—Rash—Methotrexate—bone cancer	0.00011	0.00375	CcSEcCtD
Linagliptin—Dermatitis—Methotrexate—bone cancer	0.00011	0.00374	CcSEcCtD
Linagliptin—Headache—Methotrexate—bone cancer	0.000109	0.00372	CcSEcCtD
Linagliptin—Diarrhoea—Doxorubicin—bone cancer	0.000103	0.00352	CcSEcCtD
Linagliptin—Rash—Epirubicin—bone cancer	0.000103	0.00351	CcSEcCtD
Linagliptin—Dermatitis—Epirubicin—bone cancer	0.000103	0.0035	CcSEcCtD
Linagliptin—Headache—Epirubicin—bone cancer	0.000102	0.00348	CcSEcCtD
Linagliptin—Rash—Doxorubicin—bone cancer	9.53e-05	0.00324	CcSEcCtD
Linagliptin—Dermatitis—Doxorubicin—bone cancer	9.52e-05	0.00324	CcSEcCtD
Linagliptin—Headache—Doxorubicin—bone cancer	9.47e-05	0.00322	CcSEcCtD
